Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the momentum 3 randomized trial. JAMA. 2022;328:1233–42.

Article  PubMed  PubMed Central  Google Scholar 

Kinugawa K, Sakata Y, Ono M, et al. Consensus report on destination therapy in japan - from the DT committee of the council for clinical use of ventricular assist device related academic societies. Circ J. 2021;85:1906–17.

Article  PubMed  Google Scholar 

Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307–25.

Article  CAS  PubMed  Google Scholar 

Mehra MR, Netuka I, Uriel N, et al. Aspirin and hemocompatibility events with a left ventricular assist device in advanced heart failure: the ARIES-HM3 randomized clinical trial. JAMA. 2023;330:2171–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang XW, Luo JJ, Baldinger B. The controlling nutritional status score and clinical outcomes in patients with heart failure: pool analysis of observational studies. Front Cardiovasc Med. 2022;9: 961141.

Article  PubMed  PubMed Central  Google Scholar 

Yoshimura A, Kikuchi N, Saito S, et al. Stratification of destination therapy candidates by j-heartmate risk score among elderly non-responders to cardiac resynchronization therapy. Circ Rep. 2022;4:405–11.

Article  PubMed  PubMed Central  Google Scholar 

Imamura T, Kinugawa K, Nishimura T, et al. Novel scoring system to risk stratify patients receiving durable left ventricular assist device from j-macs registry data. Circ J. 2023;87:1103–11.

Article  PubMed  Google Scholar 

van Spronsen MF, Ossenkoppele GJ, Holman R, van de Loosdrecht AA. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. Eur J Cancer. 2014;50:3198–205.

Article  PubMed  Google Scholar 

Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis: a scientific statement from the american heart association. Circulation. 2020;141:e69–92.

Article  PubMed  Google Scholar 

Toda K, Ako J, Hirayama A, et al. Three-year experience of catheter-based micro-axial left ventricular assist device, impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD). J Artif Organs. 2023;26:17–23.

Article  PubMed  Google Scholar 

Nasu T, Ninomiya R, Koeda Y, Morino Y. Impella device in fulminant myocarditis: Japanese registry for percutaneous ventricular assist device (J-PVAD) registry analysis on outcomes and adverse events. Eur Heart J Acute Cardiovasc Care. 2024;13:275–83.

Article  PubMed  Google Scholar 

Geller BJ, Sinha SS, Kapur NK, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2022;146:e50–68.

Article  PubMed  Google Scholar 

Tehrani BN, Truesdell AG, Psotka MA, et al. A standardized and comprehensive approach to the management of cardiogenic shock. JACC Heart failure. 2020;8:879–91.

Article  PubMed  PubMed Central  Google Scholar 

Yi M, Iyer P, Byku M, Hollis IB. Warfarin and aspirin versus warfarin alone for prevention of bleeding and thrombotic events in patients with a HeartMate 3™ left ventricular assist device. Artif Organs. 2024;48:98–102.

Article  CAS  PubMed  Google Scholar